90 related articles for article (PubMed ID: 23358197)
1. Assessment of plasma prothrombotic factors in patients with Buerger's disease.
Hus I; Sokolowska B; Walter-Croneck A; Chrapko M; Nowaczynska A; Dmoszynska A
Blood Coagul Fibrinolysis; 2013 Mar; 24(2):133-9. PubMed ID: 23358197
[TBL] [Abstract][Full Text] [Related]
2. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical properties in the patients with Buerger's disease--possible role of plasminogen activator inhibitor-1 for preservation of vessel wall architecture.
Sato T; Tamai H; Kobayashi M; Yamamoto K; Komori K
Cardiovasc Pathol; 2011; 20(5):266-71. PubMed ID: 20708412
[TBL] [Abstract][Full Text] [Related]
4. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans.
Undas A; Nowakowski T; Cieśla-Dul M; Sadowski J
Atherosclerosis; 2011 Apr; 215(2):481-6. PubMed ID: 21324459
[TBL] [Abstract][Full Text] [Related]
5. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): the role of tobacco antigen and the major histocompatibility complex.
Papa M; Bass A; Adar R; Halperin Z; Schneiderman J; Becker CG; Brautbar H; Mozes E
Surgery; 1992 May; 111(5):527-31. PubMed ID: 1598672
[TBL] [Abstract][Full Text] [Related]
6. Selected factors of fibrinolysis in the Buerger's disease.
Terlecki P; Feldo M; Przywara S; Iłżecki M; Kęsik JJ; Borowski G; Wroński J; Zubilewicz T
Pol Przegl Chir; 2013 Nov; 85(11):630-7. PubMed ID: 24413201
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease).
Choudhury NA; Pietraszek MH; Hachiya T; Baba S; Sakaguchi S; Takada Y; Takada A
Thromb Res; 1992 May; 66(4):321-9. PubMed ID: 1412199
[TBL] [Abstract][Full Text] [Related]
8. Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans.
Pietraszek MH; Choudhury NA; Baba S; Sakaguchi S; Hachiya T; Urano T; Takada Y; Takada A
Int Angiol; 1993 Mar; 12(1):9-12. PubMed ID: 8376917
[TBL] [Abstract][Full Text] [Related]
9. Study of the factors affecting blood viscosity in patients with thromboangiitis obliterans. A preliminary report.
Szendro G; Golcman L; Cristal N
J Vasc Surg; 1988 Jun; 7(6):759-62. PubMed ID: 3373617
[TBL] [Abstract][Full Text] [Related]
10. Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger's disease).
Park HS; Cho KH; Kim KL; Kim DK; Lee T
Vasc Med; 2013 Dec; 18(6):331-9. PubMed ID: 24292638
[TBL] [Abstract][Full Text] [Related]
11. Plasma levels of homocysteine in Buerger's sufferers and healthy heavy smokers and non-smokers.
Kenari AY; Karimi M; Salimi J; Khashayar P
Clin Lab; 2013; 59(1-2):93-6. PubMed ID: 23505912
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
13. [The prevalence of hyperhomocysteinemia in thromboangiitis obliterans. Does homocysteine play a role pathogenetically?].
Stammler F; Diehm C; Hsu E; Stockinger K; Amendt K
Dtsch Med Wochenschr; 1996 Nov; 121(46):1417-23. PubMed ID: 8974873
[TBL] [Abstract][Full Text] [Related]
14. Blood coagulation, fibrinolysis and lipid profile in patients with primary hyperparathyroidism: increased plasma factor VII and X activities and D-Dimer levels.
Erem C; Kocak M; Hacihasanoglu A; Yilmaz M; Saglam F; Ersoz HO
Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):619-24. PubMed ID: 18484067
[TBL] [Abstract][Full Text] [Related]
15. Autonomic functions in Buerger's disease.
Singh K; Sood S
Indian J Physiol Pharmacol; 2001 Oct; 45(4):470-4. PubMed ID: 11883155
[TBL] [Abstract][Full Text] [Related]
16. [Serum lipids and lipoproteins in peripheral vascular disease].
Umemoto T
Nihon Geka Gakkai Zasshi; 1985 Jan; 86(1):84-97. PubMed ID: 3974570
[TBL] [Abstract][Full Text] [Related]
17. Effect of Folic Acid therapy on Homocysteine Level in patients with Atherosclerosis or Buerger's Disease and in Healthy individuals: A clinical trial.
Modaghegh MH; Ravari H; Haghighi MZ; Rajabnejad A
Electron Physician; 2016 Oct; 8(10):3138-3143. PubMed ID: 27957316
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
Johansson JO; Landin K; Johannsson G; Tengborn L; Bengtsson BA
Thromb Haemost; 1996 Sep; 76(3):422-8. PubMed ID: 8883281
[TBL] [Abstract][Full Text] [Related]
19. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
20. Three cases of Buerger's disease associated with hyperhomocysteinemia.
Caramaschi P; Biasi D; Carletto A; Friso S; Girelli D; Arcaro G; Bambara LM
Clin Exp Rheumatol; 2000; 18(2):264-5. PubMed ID: 10812506
[No Abstract] [Full Text] [Related]
[Next] [New Search]
